Provided herein is a hydrogen chloride salt of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2- hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B, processes for the preparation of said compositions, pharmaceutical compositions prepared by said methods, and the use of said compositions in the treatment of various diseases and disorders.本案提供1-(3-第三丁基-1-對甲苯基-1H-吡唑-5-基)-3-(5-氟-2-(1-(2-羥乙基)-1H-吲唑-5-基氧基)苯甲基)脲之氯化氫鹽、1-(3-第三丁基-1-對甲苯基-1H-吡唑-5-基)-3-(5-氟-2-(1-(2-羥乙基)-1H-吲唑-5-基氧基)苯甲基)脲鹽酸鹽之晶形、用於製備該等晶形之方法、含有1-(3-第三丁基-1-對甲苯基-1H-吡唑-5-基)-3-(5-氟-2-(1-(2-羥乙基)-1H-吲唑-5-基氧基)苯甲基)脲鹽酸鹽形式B之晶形的醫藥組合物、用於製備該等組合物之方法、藉由該等方法製備之醫藥組合物，以及該等組合物用於治療各種疾病及病症的用途。
